Status:
In progress
Technology type:
Medicine
Decision:
Selected
Reason for decision:
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process:
STA Standard
ID number:
6593

Provisional Schedule

Committee meeting: 1:
23 July 2026
Expected publication:
17 September 2026

Project Team

Project lead
Thomas Feist

Email enquiries

If you have any queries please email TAteam3@nice.org.uk

Stakeholders

Companies sponsors
Arrowhead Pharmaceuticals
Others
Department of Health and Social Care
 
Health Technology Wales
 
NHS England
 
University Hospital Birmingham Foundation Trust, Department of Endocrinology
Patient carer groups
Action FCS
Professional groups
Royal College of Physicians
Assessment group
York Technology Assessment Group,
Associated public health groups
None
Comparator companies
Sobi (olezarsen) (Confidentiality agreement signed, participating)
 
Akcea Therapeutics (volanesorsen) (Confidentiality agreement not signed, not participating)
General commentators
All Wales Therapeutics and Toxicology Centre
 
British National Formulary
 
Department of Health - Northern Ireland
 
Healthcare Improvement Scotland
 
Medicines and Healthcare products Regulatory Agency
 
Scottish Medicines Consortium
 
Welsh Government
Relevant research groups
None

Timeline

Key events during the development of the guidance:

Date Update
10 December 2025 Invitation to participate
23 July 2025 - 20 August 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
23 July 2025 In progress. Scoping commenced.
10 June 2025 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual